B-Raf inhibitor vemurafenib counteracts sulfur mustard-induced epidermal impairment through MAPK/ERK signaling

References

• Arra BioPharma Inc. 2016. Investigator’s brochure encorafenib (LGX818). 8th ed. Bethesda, MD:  National Library of Medicine.
   Google Scholar
• Babin, M.C., et al., 2000. Systemic administration of candidate antivesicants to protect against topically applied sulfur mustard in the mouse ear vesicant model (MEVM). Journal of Applied Toxicology, 20 (Suppl. 1), S141–S144.
   PubMedGoogle Scholar
• Bhat, K.R., Benton, B.J., and Ray, R., 2006. Poly (ADP-ribose) polymerase (PARP) is essential for sulfur mustard-induced DNA damage repair, but has no role in DNA ligase activation. Journal of Applied Toxicology, 26 (5), 452–457.
   PubMed Web of Science ®Google Scholar
• Bhat, K.R., et al., 2000. Role of poly(ADP-ribose) polymerase (PARP) in DNA repair in sulfur mustard-exposed normal human epidermal keratinocytes (NHEK). Journal of Applied Toxicology, 20 (Suppl. 1), S13–S17.
   PubMedGoogle Scholar
• Bollag, G., et al., 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467 (7315), 596–599.
   PubMed Web of Science ®Google Scholar
• Boukamp, P., et al., 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. Journal of Cell Biology, 106 (3), 761–771.
   PubMed Web of Science ®Google Scholar
• Carr, M.J., et al., 2020. An evaluation of encorafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 21 (2), 155–161.
   PubMed Web of Science ®Google Scholar
• Davies, H., et al., 2002. Mutations of the BRAF gene in human cancer. Nature, 417 (6892), 949–954.
   PubMed Web of Science ®Google Scholar
• Delord, J.P., et al., 2017. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clinical Cancer Research, 23 (18), 5339–5348.
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer, V.C., et al., 2007. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Research, 67 (1), 122–129.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou, G., et al., 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464 (7287), 431–435.
   PubMed Web of Science ®Google Scholar
• Henry, J.R., et al., 2015. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Journal of Medicinal Chemistry, 58 (10), 4165–4179.
   PubMed Web of Science ®Google Scholar
• Karacsonyi, C., et al., 2012. Epidermal growth factor receptor signaling mediates vesicant-induced airway epithelial secretion of interleukin-6 and production of mucin. American Journal of Respiratory Cell and Molecular Biology, 46 (2), 157–164.
   PubMedGoogle Scholar
• Khazak, V., et al., 2007. Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets, 11 (12), 1587–1609.
   PubMed Web of Science ®Google Scholar
• Klaeger, S., et al., 2017. The target landscape of clinical kinase drugs. Science, 358 (6367), eaan4368.
   PubMed Web of Science ®Google Scholar
• Lehman, T.A., et al., 1993. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis, 14 (5), 833–839.
   PubMed Web of Science ®Google Scholar
• Liu, F., et al., 2016. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ, 4, e1890.
   PubMed Web of Science ®Google Scholar
• Liu, Y. and Gray, N.S., 2006. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology, 2 (7), 358–364.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay, S., et al., 2008. Activation of MAPK/AP-1 signaling pathway in lung injury induced by 2-chloroethyl ethyl sulfide, a mustard gas analog. Toxicology Letters, 181 (2), 112–117.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay, S., et al., 2009. Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome. Toxicology, 261 (3), 143–151.
   PubMed Web of Science ®Google Scholar
• Naraghi, Z.S., Mansouri, P., and Mortazavi, M., 2005. A clinicopathological study on acute cutaneous lesions induced by sulfur mustard gas (yperite). European Journal of Dermatology, 15, 140–145.
   PubMed Web of Science ®Google Scholar
• Panahi, Y., Abdolghaffari, A.H., and Sahebkar, A., 2018. A review on symptoms, treatments protocols, and proteomic profile in sulfur mustard-exposed victims. Journal of Cellular Biochemistry, 119 (1), 197–206.
   PubMed Web of Science ®Google Scholar
• Popp, T., et al., 2011. Sulfur mustard induces differentiation in human primary keratinocytes: opposite roles of p38 and ERK1/2 MAPK. Toxicology Letters, 204 (1), 43–51.
   PubMed Web of Science ®Google Scholar
• Pushpakom, S., et al., 2019. Drug repurposing: progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18 (1), 41–58.
   PubMed Web of Science ®Google Scholar
• Rebholz, B., et al., 2008. Role of NF-kappaB/RelA and MAPK pathways in keratinocytes in response to sulfur mustard. Journal of Investigative Dermatology, 128 (7), 1626–1632.
   PubMed Web of Science ®Google Scholar
• Rheault, T.R., et al., 2013. Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors. ACS Medicinal Chemistry Letters, 4 (3), 358–362.
   PubMed Web of Science ®Google Scholar
• Rose, D., et al., 2018. Sulfur mustard skin lesions: a systematic review on pathomechanisms, treatment options and future research directions. Toxicology Letters, 293, 82–90.
   PubMed Web of Science ®Google Scholar
• Rosenthal, D.S., et al., 1998. Sulfur mustard induces markers of terminal differentiation and apoptosis in keratinocytes via a Ca2+-calmodulin and caspase-dependent pathway. Journal of Investigative Dermatology, 111 (1), 64–71.
   PubMed Web of Science ®Google Scholar
• Rosenthal, D.S., et al., 2003. Expression of dominant-negative Fas-associated death domain blocks human keratinocyte apoptosis and vesication induced by sulfur mustard. Journal of Biological Chemistry, 278 (10), 8531–8540.
   PubMed Web of Science ®Google Scholar
• Roskoski, R., Jr. 2018. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 135, 239–258.
   PubMed Web of Science ®Google Scholar
• Roskoski, R., Jr. 2019. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 142, 151–168.
   PubMed Web of Science ®Google Scholar
• Savoia, P., et al., 2019. Targeting the ERK signaling pathway in melanoma. International Journal of Molecular Sciences, 20 (6), 1483.
   PubMed Web of Science ®Google Scholar
• Shi, H., et al., 2014. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discovery, 4 (1), 80–93.
   PubMed Web of Science ®Google Scholar
• Smith, W.J., 2009. Therapeutic options to treat sulfur mustard poisoning—the road ahead. Toxicology, 263 (1), 70–73.
   PubMed Web of Science ®Google Scholar
• Stuart, D.D., et al., 2012. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Experimental and Molecular Therapeutics, 72, 3790.
   Google Scholar
• Tridente, G., 2017. Chapter 15 - Vemurafenib. In: G. Tridente, ed. Adverse events and oncotargeted kinase inhibitors. New York, NY: Academic Press, 331–351.
   Google Scholar
• Williams, T.E., et al., 2015. Discovery of RAF265: a potent mut-B-RAF inhibitor for the treatment of metastatic melanoma. ACS Medicinal Chemistry Letters, 6 (9), 961–965.
   PubMed Web of Science ®Google Scholar